Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Anti-malarial Drugs Market Insights

Malaria has affected the tropical regions in the world including Africa and Asia, Central and South America, Haiti and the Dominican Republic, some parts of Middle East, and some Pacific islands. The increasing cases of traveler’s malaria is one of the factors contributing to growth of the market. Every year, thousands of people worldwide travel to such malaria affected regions, which is expected to increase the risk of infection. For instance, according to Global Health, Division of Parasitic Diseases and Malaria, and (CDC), each year, around 2,000 cases of malaria are diagnosed in the U.S. To avoid the increasing number of patient pool and to reduce the risk of traveler’s malaria, travelers are being advised by the regulatory authorities to have the antimalarial medicines with them.

The global anti-malarial drugs market was valued at US$ 839.1 million in 2019 and is expected to exhibit a CAGR of 4.4% during the forecast period (2019–2027).

Figure 1. Global Anti-malarial Drugs Market Value (US$ Mn) & Y-o-Y Growth Analysis, (2016-2027)

Anti-malaria Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing research and development activities, in order to develop novel treatment approach and collaboration among the key players are expected to drive the market growth

Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership, which was established in 1999, with an aim to reduce the burden of malaria in disease-endemic countries by developing novel treatment options. Many of the key pharmaceutical companies have been collaborating with MMV in order to develop novel drug entity for the treatment of malaria. For instance, in December 2019, Ipca Laboratories entered into a collaboration agreement with Medicines for Malaria Venture to develop a novel antimalarial co-formulation, Atoguanil, a combination of atovaquone and proguanil.

Moreover, rising funding by regional governments is significantly contributing to growth of the global anti-malaria drugs market. These funding are expected to give opportunity for research institutes such as Medicines for Malaria Venture, in order to continue the research studies for potential lead candidates targeting malaria. For instance, in November 2017, United States Agency for International Development (USAID) granted funding of US$ 9 million to Medicines for Malaria Venture for 5 years to conduct the three project including pharmacovigilance study of Pyramax (pyronaridine-artesunate), SERC Phase III study to develop a single-exposure radical cure, and to study the efficacy of DSM265, a potential single-exposure radical cure.

Adverse effects and risks associated with anti-malaria drugs is expected to hamper the global anti-malarial drugs market growth

Most of the anti-malaria drugs are associated with severe side effects, which is expected to decrease demand for these drugs. For instance, Mefloquine may lead to nausea, vomiting, abdominal pain, headache, insomnia, and vivid dreams. Some other side effects such as dizziness, loss of balance, acute anxiety, depression, restlessness, confusion, and others are also associated with Mefloquine. Such factors are expected to hamper the market growth.

Global Anti-malarial Drugs Market- Regional Analysis

On the basis of region, the global anti-malarial drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, Africa is expected to hold a dominant position in the market, owing to increasing risk of malaria in the region. For instance, according to the WHO, around 92% of malaria cases in the world occurs in the Sub- Saharan African region. WHO also estimated that, in 2017, among the five countries, which were accounted for nearly half of all malaria cases worldwide, 4 countries were from Africa region including Nigeria (25%), Democratic Republic of Congo (11%), Mozambique (5%), and Uganda (4%).

Moreover, Asia Pacific anti-malarial drugs market is expected to exhibit significant growth over the forecast period, owing to increasing regulatory approval of the products, and presence of major pharmaceutical companies such as Ipca Laboratories, Zydus Cadila, Ranbaxy, and others in the emerging economies in Asia Pacific region including India, China, and others.

Figure 2: Global Anti-malarial Drugs Market Share (%), By Region

Anti-malaria Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Global Anti-malarial Drugs Market - Competitive Landscape

Key players operating in the global anti-malarial drugs market include Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, and Roche Inc.

Malaria is common infectious disease caused by the protozoan parasite, Plasmodium parasites. The bite of an infected female Anopheles mosquito transmits a parasite to the person’s body, which then enters into the person’s liver where the production of parasite occurs. Human malaria are generally caused by five types of plasmodium parasites, including P. falciparum, P. malariae, P. ovale, P. vivax, and P.knowlesi. Among these, P. falciparum and P. vivax are the most dangerous species of parasite causing highest number of malaria mortality. Early diagnosis and efficient treatment are crucial measures to control malaria. Different types of drugs such as quinine, chloroquine, mefloquine, proguanil, primaquine, and others are used in the treatment of malaria. Moreover, some combination drugs such as Pyrimethamine & sulfadoxine, Artemether & lumefantrine, and others are also prescribed for treating the disease. According to the World Health Organization (WHO), around 91 countries and territories are at the risk of malaria transmission.

Market Dynamics

Malaria is considered as a life-threatening disease affecting large number of population across the world. According to the World Health Organization (WHO), in 2018, around 228 million estimated cases of malaria were diagnosed, globally. Moreover, global death toll due to malaria reached 405,000 in 2018 and an estimated 219 million cases were diagnosed in 2017. Sub-Saharan Africa is the most affected region due to malaria and according to WHO estimation, the region accounted for 93% of malaria cases among all the global cases. Thus, the increasing incidence of malaria in the world is expected to drive growth of the anti-malaria drugs market during the forecast period.

Moreover, various pharmaceutical companies are actively participating in research and development activities, in order to develop novel drug entity for treatment of malaria. For instance, in November 2017, Novartis Pharmaceuticals initiated phase 2 clinical trial to study the safety of the maximum dose of the investigational drug KAE609 in adult patients with uncomplicated malaria. The study is estimated to be completed in April 30, 2020. Such, increasing number of lead candidates is expected to contribute to growth of the global anti-malaria drugs market in the near future.

Key features of the study:

  • This report provides in-depth analysis of the global anti-malarial drugs market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2019 – 2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global anti-malarial drugs market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA, Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, and Roche Inc
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
  • The global anti-malarial drugs market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global anti-malarial drugs industry, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Anti-malarial Drugs Market, By Drug Class:
    • Aminoquinolines
    • Quinoline-methanol (4-quinolinemethanols)
    • Cinchona Alkaloids
    • Biguanides
    • Sulfonamides and sulfones
    • Others
  • Global Anti-malarial Drugs Market, By Route of Administration:
    • Oral
    • Injectable
  • Global Anti-malarial Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Anti-malarial Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Class:
        • Aminoquinolines
        • Quinoline-methanol (4-quinolinemethanols)
        • Cinchona Alkaloids
        • Biguanides
        • Sulfonamides and sulfones
        • Others
      • By Route of Administration:
        • Oral
        • Injectable
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Ipca Laboratories Ltd.,*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Zydus Cadila
    • Merck KGaA
    • Pfizer
    • GlaxoSmithKline Plc.
    • Cipla Ltd
    • Ranbaxy Laboratories
    • Novartis AG
    • Alvizia Health Care
    • Bayer AG
    • Roche Inc.

“*” marked represents similar segmentation in other categories in the respective section

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Mergers and Acquisitions
    • Pipeline Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
  4. Global Anti-malarial Drugs Market, By Drug Class, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Aminoquinolines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Quinoline-methanol (4-quinolinemethanols)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Cinchona Alkaloids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Biguanides
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million) Corticosteroids
    • Sulfonamides and sulfones
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  5. Global Anti-malarial Drugs Market, By Route of Administration, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
      •  
  6. Global Anti-malarial Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Anti-malarial Drugs Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Ipca Laboratories Ltd.,*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Zydus Cadila
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck KGaA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Cipla Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Ranbaxy Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Alvizia Health Care
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Roche Inc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 32 market data tables and 35 figures on "Anti-malarial Drugs Market” - Global forecast to 2027”.

Frequently Asked Questions

This report provides in-depth analysis of the global anti-malaria drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2019 – 2027). The report also provides also provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
Key segments covered in the report include: o By Drug Class o By Route of Administration o By Distribution Channel o By Region
The report provides also provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
Increasing product approval and launches by key players, increasing risk of travelers malaria, increasing prevalence of malaria in key regions such as Africa and Asia, and rising government initiatives to provide treatment to the malaria patients
The report profiles leading players in the global anti-malaria drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner